DK1754480T3 - Sammensætninger omfattende phospholipase-c-inhibitorer samt fremgangsmåde til forbedring af paracellulær permeabilitet gennem epitel- og endothelial-barrierer - Google Patents

Sammensætninger omfattende phospholipase-c-inhibitorer samt fremgangsmåde til forbedring af paracellulær permeabilitet gennem epitel- og endothelial-barrierer

Info

Publication number
DK1754480T3
DK1754480T3 DK06119516.0T DK06119516T DK1754480T3 DK 1754480 T3 DK1754480 T3 DK 1754480T3 DK 06119516 T DK06119516 T DK 06119516T DK 1754480 T3 DK1754480 T3 DK 1754480T3
Authority
DK
Denmark
Prior art keywords
phospholipase
compositions
paracellular permeability
epithelial
inhibitors
Prior art date
Application number
DK06119516.0T
Other languages
English (en)
Inventor
Dhiren R Thakker
Peter D Ward
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of DK1754480T3 publication Critical patent/DK1754480T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK06119516.0T 2000-10-10 2001-10-10 Sammensætninger omfattende phospholipase-c-inhibitorer samt fremgangsmåde til forbedring af paracellulær permeabilitet gennem epitel- og endothelial-barrierer DK1754480T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23932800P 2000-10-10 2000-10-10
EP01986603A EP1379235B1 (en) 2000-10-10 2001-10-10 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers

Publications (1)

Publication Number Publication Date
DK1754480T3 true DK1754480T3 (da) 2011-05-16

Family

ID=22901681

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01986603T DK1379235T3 (da) 2000-10-10 2001-10-10 Sammensætninger og fremgangsmåder til forbedring af paracellulær permeabilitet over epithel- og endothelbarrierer
DK06119516.0T DK1754480T3 (da) 2000-10-10 2001-10-10 Sammensætninger omfattende phospholipase-c-inhibitorer samt fremgangsmåde til forbedring af paracellulær permeabilitet gennem epitel- og endothelial-barrierer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK01986603T DK1379235T3 (da) 2000-10-10 2001-10-10 Sammensætninger og fremgangsmåder til forbedring af paracellulær permeabilitet over epithel- og endothelbarrierer

Country Status (11)

Country Link
US (1) US7713949B2 (da)
EP (2) EP1754480B1 (da)
JP (1) JP2004532795A (da)
AT (2) ATE496619T1 (da)
AU (1) AU2002224354A1 (da)
CA (1) CA2425215C (da)
DE (2) DE60125420T2 (da)
DK (2) DK1379235T3 (da)
ES (1) ES2276847T3 (da)
MX (1) MXPA03002934A (da)
WO (1) WO2002030408A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1566447A1 (en) * 2004-02-20 2005-08-24 Aventis Pharma Deutschland GmbH Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation
WO2009091986A1 (en) * 2008-01-16 2009-07-23 Lankenau Institute For Medical Research Use of proton pump inhibitors as drug delivery adjuvants
EP2506711B1 (en) 2009-12-03 2019-04-03 OPKO Health, Inc. Hypersulfated disaccharide formulations
CN108069929B (zh) * 2016-11-18 2021-06-15 中国科学院大连化学物理研究所 3-取代香豆素类衍生物及应用和gpr35受体的激动剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1511653A (en) 1974-04-16 1978-05-24 Wellcome Found Anthelmintic compositions and use
US4199507A (en) 1977-05-05 1980-04-22 The Upjohn Company Oxazole [2,3-c]-coumarin
US5373095A (en) 1985-10-18 1994-12-13 The Upjohn Company Steroid compounds
WO1987002367A2 (en) 1985-10-18 1987-04-23 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5001234A (en) 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5306830A (en) 1989-04-27 1994-04-26 The Upjohn Company Substituted 3-amino chromans
US5144045A (en) * 1990-11-13 1992-09-01 American Cyanamid Company Phosphocholine derivative inhibitors of phospholipase A2
US5208223A (en) 1990-11-13 1993-05-04 American Cyanamid Company Phosphocholine derivative inhibitors of phospholipase A2
US5234933A (en) * 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
US5580956A (en) 1992-03-11 1996-12-03 Kyowa Hakko Kogyo Co., Ltd. Phospholipase C-inhibiting peptides
DE4210332C1 (da) 1992-03-30 1993-07-15 Gruenenthal Gmbh, 5100 Aachen, De
US5238832A (en) 1992-06-08 1993-08-24 Board Of Governors Of Wayne State University Aryl aliphatic acids
AU5076293A (en) 1992-12-04 1994-06-16 F. Hoffmann-La Roche Ag Hispidospermidin
US5360815A (en) 1993-06-23 1994-11-01 Merck Frosst Canada, Inc. Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis
US5519163A (en) 1993-10-15 1996-05-21 Merck & Co., Inc. Inhibitors of phosphoinositide-specific phospholipase C
US5942246A (en) 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
CA2265631A1 (en) 1996-09-11 1998-03-19 Elizabeth Shanahan-Prendergast Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms
IL137672A0 (en) * 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof

Also Published As

Publication number Publication date
CA2425215A1 (en) 2002-04-18
MXPA03002934A (es) 2004-05-04
EP1379235B1 (en) 2006-12-20
DE60125420T2 (de) 2007-09-27
ATE496619T1 (de) 2011-02-15
DE60143975D1 (de) 2011-03-10
US20020115641A1 (en) 2002-08-22
JP2004532795A (ja) 2004-10-28
ATE348622T1 (de) 2007-01-15
DE60125420D1 (de) 2007-02-01
WO2002030408A3 (en) 2003-11-06
EP1379235A2 (en) 2004-01-14
WO2002030408A2 (en) 2002-04-18
CA2425215C (en) 2009-12-29
EP1754480A2 (en) 2007-02-21
DK1379235T3 (da) 2007-01-29
EP1754480B1 (en) 2011-01-26
AU2002224354A1 (en) 2002-04-22
EP1754480A3 (en) 2007-05-09
US7713949B2 (en) 2010-05-11
ES2276847T3 (es) 2007-07-01

Similar Documents

Publication Publication Date Title
DK1509232T3 (da) Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom
DE60220367D1 (de) Vorrichtung zum Finden von Veranstaltungen und Ereignissen sowie Navigationssystem und Anzeigeverfahren
BR9908275A (pt) Inibidores de enzimas fosfolipase
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
FR13C0022I1 (fr) C-aryl glucosides en tant qu'inhibiteurs de sglt-2 et methode correspondante
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
DK1578936T3 (da) Humane anti-IFN-gamma-neutraliserende antistoffer som selektive inhibitorer af IFN-gamma-vejen
ATE344029T1 (de) Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern
SE9803710L (sv) Användning av vissa substanser för behandling av nervrotsskador
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
DK1365762T3 (da) Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser
BR0114917A (pt) Inibidores de pirimidina-2,4,6-triona metaloproteinase
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
DK1173201T3 (da) Fremgangsmåde til behandling af fibrose ved anvendelse af en antagonist af integrin-alfa-4-underenheden
ATE399011T1 (de) Substituierte diketopiperazine als oxytocin- antagonisten
DK1333850T3 (da) Anvendelse af IL-13-inhibitorer til behandling af tumorer
DK1284720T3 (da) L-FMAU til behandling af hepatitis delta-virusinfektion
DK1754480T3 (da) Sammensætninger omfattende phospholipase-c-inhibitorer samt fremgangsmåde til forbedring af paracellulær permeabilitet gennem epitel- og endothelial-barrierer
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
AR049977A1 (es) Uso terapeutico de la toxina botulinica
WO2001087281A3 (en) Method for enhancing cognitive function
BR0111785A (pt) Composições e métodos para tratamento de candidìase
PT1276722E (pt) Inibidores de naftamidina-uroquinase